Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic ...

Pramorelin, also known in scientific literature as a synthetic ghrelin receptor agonist, has emerged as a notable peptide within the broader landscape of endocrine and metabolic research. Its primary ...

Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.

New Cell-Based Assay Supports Drug Discovery Targeting Appetite Regulation, Stress Biology, and Autonomic Function ...

The intestinal epithelium undergoes rapid renewal every 3–5 days, a process driven by intestinal stem cells (ISCs) located at the base of crypts.

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...

Corresponding author Georgios Skiniotis, PhD, St. Jude Center of Excellence for Structural Cell Biology director and Department of Structural Biology member. (MEMPHIS, Tenn. – December 22, 2025) ...

This article and associated images are based on a poster originally authored by Sam Hoare, Luciana Leo, Anastasia Schultz, and Thom Hughes and presented at ELRIG Drug Discovery 2025 in affiliation ...

Chemerin is a key adipokine—a signaling protein released by adipose tissue—that regulates lipid metabolism and insulin sensitivity and thus is involved in many metabolic diseases such as obesity and ...

Background: Human Relaxin-2 (RLN2) signals via G-protein coupled receptor (GPCR) relaxin family peptide receptor 1 (RXFP1), and exerts vasodilatory, anti-inflammatory, and anti-fibrotic effects in the ...